The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SKYE | -71.37% | -97.71% | -53.01% | -100% |
| S&P | +18.81% | +68.58% | +11.01% | +223% |
Skye Bioscience, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of cannabinoid-based therapeutics. It focuses on the treatment of a spectrum of diseases, as well as utilizing bioengineering in drug design. Its product pipeline includes SBI-100 and SBI-200. The company was founded on March 16, 2011 and is headquartered in San Diego, CA.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$180.01K | -2.7% |
| Market Cap | $24.03M | -72.0% |
| Market Cap / Employee | $2.00M | 0.0% |
| Employees | 12 | -25.0% |
| Net Income | -$14,441.96K | -48.2% |
| EBITDA | -$14,715.53K | -20.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $5.88M | -91.4% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $84.00K | -69.2% |
| Short Term Debt | $189.65K | 4.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -110.66% | -47.9% |
| Return On Invested Capital | 407.47% | -30.3% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$9,766.49K | -18.8% |
| Operating Free Cash Flow | -$9,766.49K | -19.5% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.72 | 2.19 | 2.79 | 0.71 | -37.53% |
| Price to Tangible Book Value | 0.72 | 2.19 | 2.79 | 0.71 | -37.53% |
| Enterprise Value to EBITDA | -0.37 | -6.51 | -9.24 | -0.29 | -92.16% |
| Return on Equity | -47.3% | -72.8% | -94.3% | -126.8% | 57.61% |
| Total Debt | $412.11K | $367.54K | $321.85K | $273.65K | -39.94% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
